Elucidation of the Early Infection Machinery of Hepatitis B Virus by Using Bio-nanocapsule

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Oct 28

PMID 27784961

Citations 5

Authors

Qiushi Liu

Masaharu Somiya

Shunichi Kuroda

Affiliations

Soon will be listed here.

Abstract

Currently, hepatitis B virus (HBV), upon attaching to human hepatocytes, is considered to interact first with heparan sulfate proteoglycan (HSPG) an antigenic loop of HBV envelope S protein. Then, it is promptly transferred to the sodium taurocholate cotransporting polypeptide (NTCP) the myristoylated N-terminal sequence of pre-S1 region (from Gly-2 to Gly-48, HBV genotype D), and it finally enters the cell by endocytosis. However, it is not clear how HSPG passes HBV to NTCP and how NTCP contributes to the cellular entry of HBV. Owing to the poor availability and the difficulty of manipulations, including fluorophore encapsulation, it has been nearly impossible to perform biochemical and cytochemical analyses using a substantial amount of HBV. A bio-nanocapsule (BNC), which is a hollow nanoparticle consisting of HBV envelope L protein, was efficiently synthesized in . Since BNC could encapsulate payloads (drugs, genes, proteins) and specifically enter human hepatic cells utilizing HBV-derived infection machinery, it could be used as a model of HBV infection to elucidate the early infection machinery. Recently, it was demonstrated that the N-terminal sequence of pre-S1 region (from Asn-9 to Gly-24) possesses low pH-dependent fusogenic activity, which might play a crucial role in the endosomal escape of BNC payloads and in the uncoating process of HBV. In this minireview, we describe a model in which each domain of the HBV L protein contributes to attachment onto human hepatic cells through HSPG, initiation of endocytosis, interaction with NTCP in endosomes, and consequent provocation of membrane fusion followed by endosomal escape.

Citing Articles

The Role of Orthobunyavirus Glycoprotein Gc in the Viral Life Cycle: From Viral Entry to Egress.

Gao H, Zhao D, Li C, Deng M, Li G, Chen S Molecules. 2025; 30(3).

PMID: 39942606 PMC: 11820035. DOI: 10.3390/molecules30030503.

Analysis of hepatocellular carcinoma associated with hepatitis B virus.

Zheng L J Cell Mol Med. 2023; 27(16):2271-2277.

PMID: 37517004 PMC: 10424288. DOI: 10.1111/jcmm.17867.

Bis-Benzylisoquinoline Alkaloids Inhibit Porcine Epidemic Diarrhea Virus by Disrupting Virus Entry.

Zhang C, Chen H, Sun L, Zhao P, Qi C, Yang Y Pathogens. 2023; 12(6).

PMID: 37375535 PMC: 10304817. DOI: 10.3390/pathogens12060845.

Binding of Nanoparticles Harboring Recombinant Large Surface Protein of Hepatitis B Virus to Scavenger Receptor Class B Type 1.

Hinuma S, Fujita K, Kuroda S Viruses. 2021; 13(7).

PMID: 34372540 PMC: 8310236. DOI: 10.3390/v13071334.

Peptides to combat viral infectious diseases.

Al-Azzam S, Ding Y, Liu J, Pandya P, Ting J, Afshar S Peptides. 2020; 134:170402.

PMID: 32889022 PMC: 7462603. DOI: 10.1016/j.peptides.2020.170402.

References

Leistner C, Gruen-Bernhard S, Glebe D . Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol. 2007; 10(1):122-33. DOI: 10.1111/j.1462-5822.2007.01023.x. View

Yamada M, Oeda A, Jung J, Iijima M, Yoshimoto N, Niimi T . Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. J Control Release. 2011; 160(2):322-9. DOI: 10.1016/j.jconrel.2011.11.004. View

Heermann K, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich W . Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol. 1984; 52(2):396-402. PMC: 254539. DOI: 10.1128/JVI.52.2.396-402.1984. View

Doring B, Lutteke T, Geyer J, Petzinger E . The SLC10 carrier family: transport functions and molecular structure. Curr Top Membr. 2012; 70:105-68. DOI: 10.1016/B978-0-12-394316-3.00004-1. View

Rodriguez-Crespo I, Gomez-Gutierrez J, Nieto M, Peterson D, Gavilanes F . Prediction of a putative fusion peptide in the S protein of hepatitis B virus. J Gen Virol. 1994; 75 ( Pt 3):637-9. DOI: 10.1099/0022-1317-75-3-637. View

Schulze A, Gripon P, Urban S . Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007; 46(6):1759-68. DOI: 10.1002/hep.21896. View

Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah M, VandenDriessche T . Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003; 21(8):885-90. DOI: 10.1038/nbt843. View

Kuroda S, Fujisawa Y, Iino S, Akahane Y, Suzuki H . Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine. 1991; 9(3):163-9. DOI: 10.1016/0264-410x(91)90148-y. View

Abou-Jaoude G, Sureau C . Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol. 2007; 81(23):13057-66. PMC: 2169099. DOI: 10.1128/JVI.01495-07. View

10.

Delgado C, Nunez E, Yelamos B, Gomez-Gutierrez J, Peterson D, Gavilanes F . Study of the putative fusion regions of the preS domain of hepatitis B virus. Biochim Biophys Acta. 2015; 1848(4):895-906. DOI: 10.1016/j.bbamem.2014.12.020. View

11.

Ishihara K, Waters J, Pignatelli M, Thomas H . Characterisation of the polymerised and monomeric human serum albumin binding sites on hepatitis B surface antigen. J Med Virol. 1987; 21(1):89-95. DOI: 10.1002/jmv.1890210112. View

12.

Bremer C, Bung C, Kott N, Hardt M, Glebe D . Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell Microbiol. 2008; 11(2):249-60. DOI: 10.1111/j.1462-5822.2008.01250.x. View

13.

Sureau C, Salisse J . A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology. 2012; 57(3):985-94. DOI: 10.1002/hep.26125. View

14.

Hagenbuch B, Meier P . Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994; 93(3):1326-31. PMC: 294097. DOI: 10.1172/JCI117091. View

15.

Itoh Y, Kuroda S, Miyazaki T, Otaka S, Fujisawa Y . Identification of polymerized-albumin receptor domain in the pre-S2 region of hepatitis B virus surface antigen M protein. J Biotechnol. 1992; 23(1):71-82. DOI: 10.1016/0168-1656(92)90100-n. View

16.

Bernfield M, Gotte M, Park P, Reizes O, Fitzgerald M, Lincecum J . Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 2000; 68:729-77. DOI: 10.1146/annurev.biochem.68.1.729. View

17.

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z . Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:e00049. PMC: 3485615. DOI: 10.7554/eLife.00049. View

18.

Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C . Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology. 1995; 213(2):292-9. DOI: 10.1006/viro.1995.0002. View

19.

Somiya M, Kuroda S . Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule. Adv Drug Deliv Rev. 2015; 95:77-89. DOI: 10.1016/j.addr.2015.10.003. View

20.

Matsuura Y, Yagi H, Matsuda S, Itano O, Aiura K, Kuroda S . Human liver-specific nanocarrier in a novel mouse xenograft model bearing noncancerous human liver tissue. Eur Surg Res. 2010; 46(2):65-72. DOI: 10.1159/000322491. View